Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Cell Therapeutics, Inc. (CTI) Reschedules Third Quarter 2012 Financial Results to Thursday, November 1, 2012



Cell Therapeutics, Inc. (CTI) Reschedules Third Quarter 2012 Financial Results
                        to Thursday, November 1, 2012

PR Newswire

SEATTLE, Oct. 29, 2012

SEATTLE, Oct. 29, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ
and MTA: CTIC) today announced that due to severe weather on the East Coast of
the United States related to Hurricane Sandy, CTI will now be releasing its
financial results for the third quarter 2012 on Thursday, November 1, 2012,
and will hold the related investor conference call the same day at 8:30 a.m.
Eastern/1:30 p.m. Central European/5:30 a.m. Pacific Time. CTI had previously
planned to announce its third quarter 2012 financial results on October 30,
2012.

Conference Call Numbers
Thursday, November 1
8:30 a.m. Eastern/1:30 p.m. Central European/5:30 a.m. Pacific Time
1-877-941-2333 (US Participants)
1-480-629-9773 (International)
Call-back numbers for post-listening available at 11:30 a.m. Eastern:
1- 800-406-7325 (US Participants)
1- 303-590-3030 (International)
Passcode: 4572038 #
Live audio webcast at www.celltherapeutics.com will be archived for post
listening approximately two hours after call ends.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to
developing an integrated portfolio of oncology products aimed at making cancer
more treatable. For additional information, please visit
www.CellTherapeutics.com.

Sign up for email alerts and get RSS feeds at our Web site,
http://www.CellTherapeutics.com/investors_alert

Media Contact:                      Investors Contact:
Dan Eramian                         Ed Bell
T: 206.272.4343                     T: 206.272.4345
C: 206.854.1200                     E: invest@ctiseattle.com
F: 206.272.4434                     www.celltherapeutics.com/investors
E: deramian@ctiseattle.com
www.celltherapeutics.com/press_room

 

SOURCE Cell Therapeutics, Inc.

Website: http://www.celltherapeutics.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement